In-house roundup: Antibody possession test uncertainty; fintech patent investment divide; SPCs for other industries

The US Supreme Court’s refusal to hear Amgen v Sanofi has renewed doubts over the value of antibody patents. Pharma firms such as Novartis and Bristol-Myers Squibb say they are exploring new ways to protect their innovations. Read More... 

With high R&D costs and long development timelines, some agricultural firms argue that SPCs would bolster innovation in their field. Others say these extensions don’t fit with market dynamics and are not needed. Read more... 

Financial services businesses reveal the challenges behind how they allocate their patent budgets and choose between bread-and-butter legacy tech and revolutionary solutions they could monetise to generate high returns. Read more... 

Medical device firms in the US can apply for patent term extensions if they require regulatory approval before going to market, and some in-house counsel argue that the same rules should apply to European SPCs. Read more... 

Sign up to receive more content like this in Patent Strategy’s weekly newsletter.